Skip to main
IRD

Opus Genetics (IRD) Stock Forecast & Price Target

Opus Genetics (IRD) Analyst Ratings

Based on 11 analyst ratings
Buy
Strong Buy 45%
Buy 55%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Opus Genetics is a clinical-stage biopharmaceutical company with a strong pipeline of seven AAV-based programs targeted at inherited retinal diseases (IRDs) and other retinal and refractive disorders. Their lead assets, OPGx-LCA5 and OPGx-BEST1, show great potential for treating LCA5-related mutations and BEST1-related retinal degeneration, respectively, and have upcoming data readouts in September that could trigger a potential 50-100% stock movement. The company's virtual R&D forum highlighted their strong scientific rationale and execution framework for five IRD programs, and they have reached alignment with the FDA for a streamlined Phase 3 trial design for OPGx-LCA5. However, there are still inherent risks associated with clinical trials, regulatory approvals, and commercialization timelines, and any setbacks or challenges could impact the stock price. Overall, Opus Genetics has strong potential for success in the IRD market, but investors should carefully consider the risks and monitor upcoming data readouts closely.

Bears say

Opus Genetics is facing several fundamental risks that could hinder its success and drive down its stock price. These include potential challenges in gaining regulatory approval and effectively marketing and commercializing its products, competition from emerging therapies targeting similar indications, and the inherent risk associated with investing in biotechnology companies. Additionally, with the majority of its earning potential coming from assets that are not yet commercial, Opus Genetics may struggle to secure additional funding or partnerships to finance its pipeline and achieve commercial success. Based on probability-adjusted modeling, our price target for Opus Genetics is $13, taking into consideration the company's current financials and potential future performance.

Opus Genetics (IRD) has been analyzed by 11 analysts, with a consensus rating of Buy. 45% of analysts recommend a Strong Buy, 55% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Opus Genetics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Opus Genetics (IRD) Forecast

Analysts have given Opus Genetics (IRD) a Buy based on their latest research and market trends.

According to 11 analysts, Opus Genetics (IRD) has a Buy consensus rating as of Jul 18, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $11, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $11, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Opus Genetics (IRD)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.